Tag archive for ‘hyperkalemia’
Relypsa: New Buy Recommendation on Relypsa (RLYP, Buy, $14.98)
Investment Thinking in Brief I am beginning coverage of Relypsa (RLYP) with a Buy recommendation. At this point in time, the stock is facing two major uncertainties. The launch of its first drug Veltassa (patiromer) began in December, 2015 so that the Company is fighting through all types of reimbursement and formulary access hurdles with managed […]